Revenue from ASCENIV, ADMA Biologics’ flagship immunoglobulin product, rose from $92.6 million to $362.5 million over two years. A securities class action says a good part of that climb was manufactured.
The suit, pending in the US District Court for the District of New Jersey, covers anyone who bought ADMA stock or other securities between August 9, 2024 and March 25, 2026. It accuses the company and certain officers of making materially false statements about revenue recognition, the effectiveness of internal controls and related party disclosures. The claims arise under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. These are allegations, and the court has decided nothing.
The related party
The complaint’s central charge is about a distributor. It alleges ADMA hid its sales to Genesis BioPharma Services, a related party that operated out of the company’s own corporate headquarters in Ramsey, New Jersey. What ADMA disclosed, according to the complaint, were purchases by a similarly named entity, GenesisBPS. The plaintiffs say leaving out the first name broke SEC rules on disclosing related party transactions.
They call the result a de facto channel stuffing scheme: shipping product into the distribution chain to make revenue growth look better than demand supported.
The reported growth is where the numbers get awkward. ADMA reported 20% revenue growth for 2025. The lawsuit says that figure was a fabrication, and it cites a March 2026 research report estimating that, without the alleged stuffing, revenue fell about 3% from the year before.
What investors can do now
The court set August 10, 2026 as the deadline to apply to be lead plaintiff, the investor chosen to represent the whole class. The court usually picks the one with the largest documented losses. Law firm Levi & Korsinsky, which put out the notice, says that applying does not raise a person’s own recovery but gives control over how the case is run. Investors who bought during the class period may be eligible whether or not they still hold the shares, and the firm says such cases run on contingency, with no upfront fees. It adds that securities class actions typically take two to four years to resolve.





